SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art

Abstract Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) con...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif, Ena Wang, on behalf of the Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2018-12-01
Collection:Journal for ImmunoTherapy of Cancer
Sujets:
Biomarkers
Cancer immunotherapy
PD-1/PD-L1
Checkpoint inhibitor
Accès en ligne:http://link.springer.com/article/10.1186/s40425-018-0453-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires